KLRC1
NKG2-A/NKG2-B type II integral membrane protein
As of the edition of 20 October 2026, KLRC1 (NKG2-A/NKG2-B type II integral membrane protein, UniProt P26715) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P26715
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Ear, nose and throat; Immune system; Infections; Pregnancy and women's health
- Registered trials of its drugs
- 26
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Monalizumab | Active | Phase 3 | none listed |
| S095029 | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Innate Pharma | Route A |
The other 2 companies at KLRC1
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at KLRC1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.